

A Comparison of Refractive Accuracy Between Conventional and Femtosecond Laser Cataract Surgery Techniques Using Modern IOL Formulas

This article was published in the following Dove Press journal: Clinical Ophthalmology

Benjamin J Connell^{1,2} Jack X Kane² Rasik B Vajpayee (p²⁻⁴

¹Eye Surgery Associates, Melbourne, Victoria, Australia; ²Corneal Unit, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; ³Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia; ⁴Vision Eye Institute, Melbourne, Victoria, Australia **Purpose:** To compare the refractive outcome prediction accuracy between conventional (CCS) and femtosecond laser assisted (FLACS) cataract surgery techniques using optimized lens constants for modern intraocular lens (IOL) formulas.

Patients and Methods: Our retrospective, comparative, interventional case series, compared data from 196 eyes undergoing CCS and 456 eyes undergoing FLACS with Acrysof IOL (Alcon laboratories, Inc) implantation. After optimizing IOL constants, the predicted refractive outcome was calculated for all formulas for each case. This was compared to the actual refractive outcome to provide the prediction error. The performance of CCS and FLACS was compared by the absolute prediction error and percentage of eyes within 0.25D, 0.5D and 1.0D of anticipated refractive outcome.

Results: There was no statistically significant difference in median absolute error between the CCS and LACS groups for the Kane (0.256, 0.236; p=0.389), SRK T (0.298, 0.302, p=0.910), Holladay (0.312, 0.275; p=0.090), Hoffer Q (0.314, 0.289; p=0.330), Haigis (0.309, 0.258; p=0.177), Barrett Universal 2(0.250, 0.250; p=0.866), Holladay 2 (0.250, 0.258; p=0.860) and Olsen (0.260, 0.255; p=0.570) formulas. Similarly, there was no consistent difference between the two techniques for percentage of patients within 0.25, 0.50 and 1.0D of predicted refractive outcome for each formula.

Conclusion: There was no difference in refractive outcome prediction accuracy between the CCS and FLACS techniques.

Keywords: femtosecond laser-assisted cataract surgery, refractive predictability, IOL formulas

Introduction

Recent generation of IOL formulas have significantly improved the refractive outcome prediction accuracy of modern cataract surgery. The ability of modern IOL formulas to achieve superior refractive outcomes over earlier third generation formulas^{1–3} has been possible due to their accuracy at predicting the effective lens position. Recent large studies^{4–7} comparing CCS and FLACS have demonstrated no clear differences in prediction of refractive accuracy using earlier IOL formulas. However, none of these studies undertook the recommended⁸ IOL constant optimization to eliminate the source of bias inherent to IOL constants recommended by manufacturers.

We postulated that the improved precision of modern formulas, together with IOL constant optimization, may demonstrate that the superior capsulotomy

Correspondence: Benjamin J Connell Eye Surgery Associates, 2/232 Victoria Pde, East Melbourne, VIC, 3002, Australia Tel +61 9416 0695 Fax +61 9416 1816 Email benconnell@outlook.com.au geometry and IOL position^{9,10} advantages with FLACS translates into improved refractive outcomes.

In the present study, we investigated whether refractive outcome predictions were more accurate in FLACS when compared with CCS using optimized IOL constants for modern IOL formulas.

Patients and Methods

This retrospective, comparative, interventional comparative case series included all patients that had undergone CCS or FLACS surgery performed by a single surgeon (BC) between July 2015 and July 2019. Patients who had co-morbidities such as corneal scarring or previous ocular surgery were excluded. Other exclusion criteria were occurrence of intraoperative or postoperative complications or patients who had post-operative vision less than 6/12 (20/40) equivalent.

If both eyes from a single patient met the inclusion criteria, one eye was randomly chosen for inclusion in the analysis. The study was approved by the Royal Victorian Eye and Ear Hospital Human Research Ethics Committee. Individual patient consent was not required as no patient identifying data was stored and retrospective study design, in compliance with the local data privacy laws. The study was conducted in compliance with the Declaration of Helsinki.

Preoperative and Postoperative Examinations

Patients underwent a preoperative full visual acuity assessment, slit lamp anterior and posterior segment examination. Preoperative biometry was performed using the IOLMaster model 700 (Carl Zeiss Meditec AG).

Group Allocation

The population typically held private health insurance and each patient self-selected either technique based on their own preference, considering the increased out of pocket expense for the laser assisted technique.

Surgical Techniques

The same surgeon (BC) performed all surgeries in a private operating facility under topical anesthesia. Capsulotomies were centered on the pupil. After removal of the cataract, an Alcon SN60WF or Alcon T6 series (Alcon Laboratories, Fort Worth Texas) IOL was injected. The wound was enlarged only for higher powered IOLs, as

per the manufacturer's recommendation. Postoperative management was identical for the two groups. Prednisolone acetate 1% (Prednefrin Forte, Allergan) and Chloramphenicol 0.5% (Chlorsig, Sigma Pharmaceuticals, Australia) were used four times per day for 4 weeks following surgery.

Conventional Technique

In this technique, clear corneal temporal 2.4mm wounds were used and the capsulotomy performed using forceps, followed by traditional phacoemulsification.

Femtosecond Laser Technique

The laser (LenSx platform, Alcon Surgical Inc) was used to perform the capsulotomy, lens fragmentation and wound construction. The pupil centered capsulotomy was used with the following parameters: 4.9mm diameter, with delta up 270 μ m, delta down 330 μ m, spot energy 6.50 μ J, spot separation 4μ m and layer separation 4μ m. Traditional phacoemulsification was then used to remove the nucleus.

Formulas to Predict Post-Operative Spherical Equivalent Outcome

Haigis,¹¹ Hoffer Q,^{12,13} Holladay¹⁴ and SRK/T¹⁵ formulas were programmed into a previously validated¹⁶ Excel spreadsheet (Microsoft, Redmond, Washington, USA) using the original publications and errata.

Data was entered into the respective third-party calculators for the other formulas: PhacoOptics program for the Olsen formula, ¹⁷ IOL Consultant software for the Holladay 2 formula, ¹⁸ and online calculators for the Barrett Universal 2. ¹⁹ The Kane formula was calculated by one of the authors (JK).

The constant for each formula was optimized to produce a mean prediction error of zero (or as close as possible) by performing multiple iterations of the data using varying constants. For the Haigis formula, results were included for single (a_0) and triple constant optimization.

For some formulas, a mean prediction error of zero could not be obtained due to limitations in how many decimal places could be entered for the constant into the calculator. In these cases the small residual mean error was removed by adjusting the refractive prediction error for each eye by an amount equal to the mean prediction error in that group as described in the JCRS editorial by Wang et al.²⁰

Dovepress Connell et al

Statistical Analysis

All statistical analysis was performed using Stata IC version 14 (College Station, TX, USA). Categorical variables were compared between surgical technique groups with Fisher's exact test. The distribution of continuous variables was assessed with the Shapiro–Wilk normality test and then the CCS and FLACS groups were compared using the two-sample *t*-test for normally-distributed variables and the Wilcoxon rank-sum test if the variable was not normally distributed.

Results

During the study period 352 CCS and 826 FLACS procedures were performed. After exclusions, 196 eyes (from 196 patients) were included in the CCS group and 456 eyes (from 456 patients) in the FLACS group. Details of the exclusions are show in Table 1.

Small, statistically significant differences were noted in the median for baseline demographics between the two groups (Table 2). The CCS group was older (75 v 73 years; p=0.008), had shorter axial length (23.33 v 23.66mm; p=0.028), anterior chamber depth (3.03 v 3.14mm; p=0.002), thicker lens (4.71 v 4.59mm; p=<0.001) and inferior post-operative corrected distance visual acuity (0.00 v 0.00; p = 0.005).

There was no statistically significant difference in gender proportions (37/40% Male) or toric IOL use (71% for both) between the CCS/FLACS groups. The groups displayed similar distributions of certain comorbidities (Table 3). Optimized constants are shown in Table 4.

There was no statistically significant difference in the median absolute error between the CCS and FLACS groups for any of the formulas (Table 5). There was also no difference in percentage of patients within 0.25, 0.50 and 1.00 D of predicted refraction for the CCS compared

to the FLACS group (Table 6) for any of the formulas with the only exception the single constant optimized Haigis formula, where the percentage achieving within 1.0D of predicted was statistically higher in the FLACS group (98.5% v 95.9%; p=0.047).

Discussion

A femtosecond capsulotomy used in FLACS is considered geometrically superior to the manual capsulotomy in CCS. Studies have demonstrated it to have a more predictable diameter, 9,21-24 more circular, 9,21-25 less eccentric, 9,23,24 and less shrinkage post-operatively. Consequently, the IOL position in FLACS demonstrates less tilt, 10 decentration, 10 greater overlap of the optic 9 and the post-operative IOL anterior-posterior position deviates less from predicted. 21

Effective lens position has been shown to be the most important factor in refractive prediction accuracy.²⁷ We hypothesized, that the superior FLACS capsulotomy geometry when compared with CCS, might translate improved in refractive accuracy by improving the predictability of the effective lens position.

Clinical studies to date have typically used 3rd generation formulas and not consistently demonstrated a refractive benefit for FLACS. The FEMCAT,⁴ FACT⁵ and Roberts²⁸ randomized control trials, a prospective intraindividual trial,²⁹ the EUREQUO registry³⁰ and retrospective studies by Berk⁶ and Chee,⁷ have all used 3rd generation formulas and relatively large numbers have not demonstrated any refractive advantage. Ewe and colleagues,³¹ in a prospective, non-randomized comparative study demonstrated an advantage for CCS over FLACS.

Only a few smaller studies, also using 3rd generation formulas, have identified a refractive advantage for FLACS. A prospective study of 132 eyes³² published in 2012 reported the mean absolute error was less with

Table I Indications for Subject Exclusion from the Analysis

Exclusion Indication	CCS (352 Surgeries)		FLACS (826 Surgeries)	
	N Excluded	(Total Remaining)	N Excluded	(Total Remaining)
Co-morbidities	23	(329)	67	(759)
Intra operative complication	1	(328)	2	(757)
Missing post-operative subjective refraction	0	(328)	2	(755)
Post-operative VA worse than 6/12	6	(322)	19	(736)
Missing biometry (unable to measure AXL or K's)	0	(322)	2	(734)
Random exclusion of I eye where both eyes eligible	126	(196)	278	(456)
Final counts	196		456	

Table 2 Baseline Demographic and Clinical Characteristics

	ccs	FLACS	P value*
Age (y)			
Mean (95% CI)	74.0 (72.7,75.3)	72.4 (71.5, 73.2)	
Median (IQR)	75.0 (70.0, 80.0)	73.0 (67.0, 79.0)	0.008
Gender			
Male, n (%)	73 (37.2)	184 (40.4)	0.485
Pre op UDVA (logMAR)			
Mean (95% CI)	0.58 (0.53, 0.64)	0.60 (0.56, 0.64)	
Median (IQR)	0.60 (0.40, 0.80)	0.50 (0.30, 0.80)	0.840
Pre op CDVA (logMAR)			
Mean (95% CI)	0.20 (0.17, 0.22)	0.20 (0.18, 0.22)	
Median (IQR)	0.20 (0.10, 0.30)	0.20 (0.10, 0.30)	0.475
Axial length (mm)			
Mean (95% CI)	23.62 (23.45, 23.79)	23.79 (23.67,23.91)	
Median (IQR)	23.33 (22.84, 24.14)	23.66 (22.97, 24.50)	0.028#
Anterior chamber depth (mm)			
Mean (95% CI)	3.05 (3.00, 3.11)	3.15 (3.11, 3.18)	
Median (IQR)	3.03 (2.77, 3.29)	3.14 (2.88, 3.39)	0.002#
Lens thickness (mm)			
Mean (95% CI)	4.70 (4.64, 4.76)	4.59 (4.55, 4.63)	
Median (IQR)	4.71 (4.42, 4.99)	4.59 (4.29, 4.87)	<0.001#
Mean keratometry (D)			
Mean (95% CI)	43.92 (43.70, 44.14)	43.79 (43.65, 43.93)	
Median (IQR)	43.91 (42.81, 44.91)	43.75 (42.75, 44.89)	0.393
Corneal astigmatism (D)			
Mean (95% CI)	0.96 (0.86, 1.05)	0.89 (0.83, 0.96)	
Median (IQR)	0.81 (0.50, 1.28)	0.76 (0.43, 1.10)	0.091
Central corneal thickness (µm)			
Mean (95% CI)	548 (543, 553)	553 (549, 556)	
Median (IQR)	546 (527, 565)	553 (529, 574)	0.044#
Horizontal white to white (mm)			
Mean (95% CI)	11.92 (11.85, 11.98)	11.98 (11.94, 12.02)	
Median (IQR)	11.90 (11.65, 12.30)	12.00 (11.70, 12.30)	0.281
Pupil diameter (mm)			
Mean (95% CI)	3.83 (3.68, 3.97)	3.75 (3.67, 3.84)	
Median (IQR)	3.60 (3.10, 4.35)	3.60 (3.10, 4.20)	0.561
Post op UDVA (logMAR)			
Mean (95% CI)	0.28 (0.25, 0.32)	0.27 (0.24, 0.29)	
Median (IQR)	0.20 (0.10, 0.40)	0.20 (0.10, 0.40)	0.274
Post op refractive astigmatism (D)			
Mean (95% CI)	0.42 (0.36, 0.47)	0.39 (0.36, 0.42)	
Median (IQR)	0.50 (0.00, 0.50)	0.50 (0.00, 0.50)	0.475
Post op spherical equivalent (D)			
Mean (95% CI)	-0.91 (-1.03, -0.79)	-0.90 (-0.98, -0.83)	
Median (IQR)	-0.75 (-1.25, -0.38)	-0.75 (-1.25, -0.38)	0.682

(Continued)

Dovepress Connell et al

Table 2 (Continued).

	ccs	FLACS	P value*
Post op CDVA (logMAR)			
Mean (95% CI)	0.02 (0.00, 0.03)	-0.01 (-0.02, 0.00)	
Median (IQR)	0.00 (-0.10, 0.10)	0.00 (-0.10, 0.00)	0.005#

Notes: *p value relates to the Wilcoxon Rank-Sum test for continuous variables and Fisher exact test for gender and IOL type. *Statistically significant difference between surgical technique groups.

Abbreviations: CI, confidence interval; IQR, interquartile range, UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; D, dioptres.

Table 3 Comorbidity Counts

Comorbidity	ccs	FLACS	P value*
Amblyopia, n (%)	3 (1.5)	5 (1.1)	0.702
Fuchs endothelial dystrophy, n (%)	I (0.5)	13 (2.9)	0.076
Past pterygium surgery, n (%)	2 (1.0)	6 (1.3)	1.000
Current prostaglandin drop use, n (%)	10 (5.1)	21 (4.6)	0.841
Glaucoma involving fixation, n (%)	2 (1.0)	2 (0.4)	0.588
Pseudoexfoliation syndrome, n (%)	2 (1.0)	12 (2.6)	0.249
Oral alpha agonist use, n (%)	2 (1.0)	9 (2.0)	0.519
Past vitrectomy, n (%)	0	5 (1.1)	0.329
Past retinal detachment, n (%)	0	3 (0.7)	0.558
Epiretinal membrane, n (%)	5 (2.6)	13 (2.9)	1.000
Age related maculopathy, n (%)	17 (8.7)	47 (10.3)	0.569
Diabetes, n (%)	16 (8.2)	34 (7.5)	0.750
Diabetic retinopathy, n (%)	3 (1.5)	I (0.2)	0.084

Note: *p value relates to Fisher exact test for difference between surgical technique groups.

FLACS (0.5/0.38D, p=0.04). A prospective intraindividual study by Conrad-Hengerer³³ with one eye of 100 patients randomized to each technique published in 2015

demonstrated 71/92% (p<0.05) of eyes within 0.5 D of the intended outcome for CCS/FLACS. An accuracy of 92% of eyes achieving within 0.5D for FLACS

Table 4 Constants Used for the Different Formulas

Formula	Constant	SN60WF	SN6ATx
SRKT		118.72	118.91
Holladay I		1.63	1.77
Hoffer Q		5.41	5.56
Haigis single optimisation	a0 a1 a2	-0.990 0.234 0.217	-0.828 0.234 0.217
Haigis triple optimisation	a0 a1 a2	-0.165 0.359 0.166	-0.590 0.408 0.184
Barrett Universal 2		118.71	118.96
Olsen	ACD const.	4.43 0.340	4.56 0.368
Holladay 2		5.281	5.409
Kane		118.66	118.89

demonstrated in the Conrad-Hengerer study is relatively high and has not been replicated in other studies. For example, our study with modern biometry, optimized constants and strict case exclusion criteria demonstrated only 72/74% (SRK/T) and 79/81% (Haigis) from the CCS/ FLACS groups were within 0.5D of the intended outcome. Other large studies^{5,6,28,31,34} have typically reported 75% or less and no more than 83%, in either group, achieving within 0.5D of the intended outcome.

More recent relatively small studies, also using older 3rd formulas, have only demonstrated a benefit for FLACS on some outcome measures. A recent retrospective study with 50 cases in each group, reported a significantly greater percentage of eyes within 0.5D of the intended outcome (48/76%, p = 0.01) but no difference between groups for the mean absolute error. In this study, there was a mean prediction error difference between the groups (-0.42/-0.11) because they did not optimize their lens constants. This difference in mean prediction error likely explains the difference in mean absolute errors reported. A large retrospective comparative case series with 3144 eyes³⁴ demonstrated a statistically significant lower mean absolute error for FLACS compared with CCS (0.60 v 0.54D) however there was no difference in percentage of patients within 0.5D of intended.

None of these studies had used modern IOL formulas such as the Barrett Universal 2, Olsen or Kane formulas which have been reported to be more accurate than third generation

Table 5 Prediction and Absolute Errors for Each Formula

	Prediction Error	Absolute Error		
	All Eyes	ccs	FLACS	p *
Kane				
Mean (95% CI)	0.000 (-0.029, 0.029)	0.312 (0.277, 0.347)	0.289 (0.268, 0.309)	
Median (IQR)	0.021 (-0.237, 0.246)	0.256 (0.135, 0.433)	0.236 (0.119, 0.410)	0.389
SRKT				
Mean (95% CI)	0.000 (-0.035, 0.035)	0.362 (0.322, 0.403)	0.363 (0.337, 0.389)	
Median (IQR)	0.007 (-0.293, 0.312)	0.298 (0.148, 0.514)	0.302 (0.150, 0.518)	0.910
Holladay I				
Mean (95% CI)	0.000 (-0.033, 0.033)	0.368 (0.330, 0.406)	0.330 (0.307, 0.354)	
Median (IQR)	0.003 (-0.280, 0.290)	0.312 (0.165, 0.505)	0.275 (0.136, 0.460)	0.090
Hoffer Q				
Mean (95% CI)	0.000 (-0.034, 0.034)	0.373 (0.334, 0.413)	0.344 (0.321, 0.368)	
Median (IQR)	0.014 (-0.283,0.305)	0.314 (0.145, 0.555)	0.289 (0.140, 0.498)	0.330
Haigis				
Mean (95% CI)	0.000 (-0.031, 0.031)	0.344 (0.306, 0.382)	0.308 (0.286, 0.330)	
Median (IQR)	0.006 (-0.260,0.291)	0.309 (0.139, 0.467)	0.258 (0.122, 0.442)	0.177
Haigis Triple				
Mean (95% CI)	0.000 (-0.031, 0.031)	0.333 (0.295, 0.372)	0.304 (0.282, 0.326)	
Median (IQR)	0.011 (-0.259,0.273)	0.272 (0.128, 0.464)	0.262 (0.119, 0.417)	0.326
Barrett Univ.2				
Mean (95% CI)	0.000 (-0.030, 0.030)	0.314 (0.276, 0.352)	0.300 (0.278, 0.321)	
Median (IQR)	0.015 (-0.232,0.253)	0.250 (0.122, 0.435)	0.250 (0.110, 0.425)	0.866
Holladay 2				
Mean (95% CI)	0.000 (-0.029, 0.032)	0.316 (0.280, 0.352)	0.307 (0.285, 0.329)	
Median (IQR)	0.007 (-0.240,0.263)	0.250 (0.132, 0.430)	0.258 (0.132, 0.415)	0.860
Olsen				
Mean (95% CI)	-0.002 (-0.033, 0.028)	0.320 (0.284, 0.355)	0.303 (0.281, 0.324)	
Median (IQR)	-0.003 (-0.250,0.260)	0.260 (0.115, 0.440)	0.255 (0.130, 0.420)	0.570

Note: *p value relates to the Wilcoxon rank-sum test for difference between groups.

Abbreviations: Cl, confidence interval; IQR, interquartile range.

Dovepress Connell et al

Table 6 % of Eyes Within 0.25, 0.50 and 1.0D of Absolute Error

Kane ≤0.25 D (95% Cl) 49.5% (42.5, 56.5) 54.0% (49.4, 58.5) 0.296 81.6% (76.2, 87.1) 81.0 D (95% Cl) 98.0% (96.0, 99.9) 99.1% (98.3, 100.0) 0.216 SRKT ≤0.25 D (95% Cl) 39.8% (32.9, 46.7) 41.0% (36.5, 45.5) 0.772 ≤1.0 D (95% Cl) 96.4% (93.8, 99.0) 96.5% (94.8, 98.2) 0.968 Holladay I ≤0.25 D (95% Cl) 51.0 D (95% Cl) 39.8% (32.9, 46.7) 43.2% (38.7, 47.8) 0.419 ≤0.55 D (95% Cl) 51.0 D (95% Cl) 96.9% (94.5, 99.4) 98.0% (96.8, 99.3) 0.396 Hoffer Q ≤0.25 D (95% Cl) ≤0.5 D (95% Cl) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 50.5 D (95% Cl) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.25 D (95% Cl) 42.4% (35.4, 49.3) ≤1.0 D (95% Cl) 42.4% (35.4, 49.3) ≤1.0 D (95% Cl) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 Haigis Triple ≤0.25 D (95% Cl) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 3.05 D (95% Cl) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 3.05 D (95% Cl) 51.0 D (95% Cl) 51.0 D (95% Cl) 51.0 D (95% Cl) 51.0 P(95% Cl) 50.5 D (95% Cl) 51.0 P(95% Cl) 50.5 D (95% Cl) 50		ccs	FLACS	P *
\$0.5 D (95% CI)	Kane			
≤1.0 D (95% Cl) 98.0% (96.0, 99.9) 99.1% (98.3, 100.0) 0.216 SRKT ≤0.25 D (95% Cl) 39.8% (32.9, 46.7) 41.0% (36.5, 45.5) 0.772 ≤0.5 D (95% Cl) 71.9% (65.7, 78.2) 73.9% (69.9, 77.9) 0.603 ≤1.0 D (95% Cl) 96.4% (93.8, 99.0) 96.5% (94.8, 98.2) 0.968 Holladay I ≤0.25 D (95% Cl) 39.8% (32.9, 46.7) 43.2% (38.7, 47.8) 0.419 ≤0.5 D (95% Cl) 74.0% (67.8, 80.1) 79.0% (75.2, 82.7) 0.164 ≤1.0 D (95% Cl) 96.9% (94.5, 99.4) 98.0% (96.8, 99.3) 0.396 Hoffer Q 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.5 D (95% Cl) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.5 D (95% Cl) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis 50.5 D (95% Cl) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤1.0 D (95% Cl) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple 50.5 D (95% Cl) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% Cl) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 <	≤0.25 D (95% CI)	49.5% (42.5, 56.5)	54.0% (49.4, 58.5)	0.296
SRKT ≤0.25 D (95% CI) 39.8% (32.9, 46.7) 71.9% (65.7, 78.2) 73.9% (69.9, 77.9) 0.603 ≤1.0 D (95% CI) 96.4% (93.8, 99.0) 96.5% (94.8, 98.2) 0.968 Holladay I ≤0.25 D (95% CI) 39.8% (32.9, 46.7) 74.0% (67.8, 80.1) 96.9% (94.8, 99.3) 0.396 Hoffer Q ≤0.25 D (95% CI) 43.4% (36.4, 50.3) ≤1.0 D (95% CI) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.5 D (95% CI) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis ≤0.25 D (95% CI) 42.4% (35.4, 49.3) ≤1.0 D (95% CI) 42.4% (35.4, 49.3) ≤1.0 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 51.0 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 30.5 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 30.5 D (95% CI) 50.5 D (95% CI) 50.5 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 20.25 D (95% CI) 50.5 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 Holladay 2 ≤0.25 D (95% CI) 50.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 50.5 D (95% CI) 50.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 50.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 50.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 50.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.0, 54.2) 0.892 50.25 D (95% CI) 50.5 D (9	≤0.5 D (95% CI)	81.6% (76.2, 87.1)	84.4% (81.1, 87.8)	0.377
\$\text{SD}\$ D (95\times CI)\$ \$\text{SD}\$ 0.5 D (95\times CI)\$ \$\text{SI}\$ 0.0 D (95\times CI)\$ \$\t	≤1.0 D (95% CI)	98.0% (96.0, 99.9)	99.1% (98.3, 100.0)	0.216
\$0.5 D (95% CI)	SRKT			
≤1.0 D (95% CI) 96.4% (93.8, 99.0) 96.5% (94.8, 98.2) 0.968 Holladay I ≤0.25 D (95% CI) 39.8% (32.9, 46.7) 43.2% (38.7, 47.8) 0.419 ≤0.5 D (95% CI) 74.0% (67.8, 80.1) 79.0% (75.2, 82.7) 0.164 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.0% (96.8, 99.3) 0.396 Hoffer Q <0.25 D (95% CI)	≤0.25 D (95% CI)	39.8% (32.9, 46.7)	41.0% (36.5, 45.5)	0.772
Holladay I ≤0.25 D (95% CI) 39.8% (32.9, 46.7) 74.0% (67.8, 80.1) 79.0% (75.2, 82.7) 0.164 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.0% (96.8, 99.3) 0.396 Hoffer Q ≤0.25 D (95% CI) 43.4% (36.4, 50.3) ≤1.0 D (95% CI) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.5 D (95% CI) 68.9% (62.4, 75.4) 75.2% (71.3, 79.2) 0.093 ≥1.0 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) ≤1.0 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 30.823 ≥1.0 D (95% CI) 80.6% (75.1, 86.2) ≥1.0 D (95% CI) 80.6% (75.1, 86.2) ≥0.25 D (95% CI) ≤0.25 D (95% CI) 51.0% (44.0, 58.0) ≤1.0 D (95% CI) 51.0% (44.0, 58.0) ≤1.0 D (95% CI) 51.0% (44.0, 58.0) ≤0.5 D (95% CI) ≤0.5 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≥0.25 D (95% CI) 51.0% (44.1, 58.2) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≥0.5 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) ≤0.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128	≤0.5 D (95% CI)	71.9% (65.7, 78.2)	73.9% (69.9, 77.9)	0.603
\$\(\begin{array}{c c c c c c c c c c c c c c c c c c c	≤1.0 D (95% CI)	96.4% (93.8, 99.0)	96.5% (94.8, 98.2)	0.968
SO.5 D (95% CI) 74.0% (67.8, 80.1) 79.0% (75.2, 82.7) 0.164 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.0% (96.8, 99.3) 0.396 Hoffer Q ≤0.25 D (95% CI) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.5 D (95% CI) 68.9% (62.4, 75.4) 75.2% (71.3, 79.2) 0.093 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis ≤0.25 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.25 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128	Holladay I			
SO.5 D (95% CI) 74.0% (67.8, 80.1) 79.0% (75.2, 82.7) 0.164 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.0% (96.8, 99.3) 0.396 Hoffer Q ≤0.25 D (95% CI) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 0.949 ≤0.5 D (95% CI) 68.9% (62.4, 75.4) 75.2% (71.3, 79.2) 0.093 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis ≤0.25 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.25 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128	≤0.25 D (95% CI)	39.8% (32.9, 46.7)	43.2% (38.7, 47.8)	0.419
Hoffer Q ≤0.25 D (95% CI) ≤0.5 D (95% CI) ≤1.0 D (95% CI) 43.4% (36.4, 50.3) 43.6% (39.1, 48.2) 75.2% (71.3, 79.2) 0.093 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis ≤0.25 D (95% CI) 42.4% (35.4, 49.3) √9.1% (73.4, 84.8) √9.1% (77.3, 84.5) √9.1% (73.4, 84.8) 80.9% (77.3, 84.5) √9.5% (93.2, 98.7) Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) √9.5% (1) √9.5% (1) √9.9% (94.5, 99.4) √98.5% (97.3, 99.6) 0.621 80.6% (75.1, 86.2) √98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 √0.25 D (95% CI) √0.5 D (95% CI) √0.6 (74.0, 85.2) √0.6 (75.0, 90.7) √0.6 (75.0, 90.7) √0.6 (75.0, 90.7) √0.128		74.0% (67.8, 80.1)	79.0% (75.2, 82.7)	0.164
≤0.25 D (95% CI)	≤1.0 D (95% CI)	96.9% (94.5, 99.4)	98.0% (96.8, 99.3)	0.396
≤0.25 D (95% CI)	Hoffer Q			
≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis ≤0.25 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	-	43.4% (36.4, 50.3)	43.6% (39.1, 48.2)	0.949
≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.0% (96.8, 99.3) 0.641 Haigis ≤0.25 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤0.5 D (95% CI)	68.9% (62.4, 75.4)	75.2% (71.3, 79.2)	0.093
≤0.25 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509		97.5% (95.2, 99.7)	98.0% (96.8, 99.3)	0.641
≤0.25 D (95% CI) 42.4% (35.4, 49.3) 48.7% (44.1, 53.3) 0.137 ≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	Haigis			
≤0.5 D (95% CI) 79.1% (73.4, 84.8) 80.9% (77.3, 84.5) 0.588 ≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	_ ~	42.4% (35.4, 49.3)	48.7% (44.1, 53.3)	0.137
≤1.0 D (95% CI) 95.9% (93.2, 98.7) 98.5% (97.3, 99.6) 0.047 Haigis Triple ≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	, , ,	, , ,	, , ,	0.588
≤0.25 D (95% CI) 45.9 (38.9, 52.9) 48.0% (43.4, 52.6) 0.621 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤1.0 D (95% CI)	95.9% (93.2, 98.7)	98.5% (97.3, 99.6)	0.047
≤0.5 D (95% CI) 80.6% (75.1, 86.2) 81.4% (77.8, 84.9) 0.823 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	Haigis Triple			
≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.5% (97.3, 99.6) 0.201 Barrett Univ. 2 ≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤0.25 D (95% CI)	45.9 (38.9, 52.9)	48.0% (43.4, 52.6)	0.621
Barrett Univ. 2 ≤0.25 D (95% CI) ≤0.5 D (95% CI) ≤0.5 D (95% CI) ≤1.0 D (95% CI) ≤1.0 D (95% CI) ≤1.0 D (95% CI) Example 2 (95.2 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 60.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 60.5 D (95% CI) 60.6 Place 2 60.25 D (95% CI) 60.25 D (95% CI) 60.25 D (95% CI) 60.25 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 82.5% (79.0, 86.0) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 80.1% (79.5, 99.4) 80.5% (97.6, 99.7) 80.6% (45.0, 54.2) 80.892	≤0.5 D (95% CI)	80.6% (75.1, 86.2)	81.4% (77.8, 84.9)	0.823
≤0.25 D (95% CI) 51.0% (44.0, 58.0) 51.5% (47.0, 56.1) 0.904 ≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤1.0 D (95% CI)	96.9% (94.5, 99.4)	98.5% (97.3, 99.6)	0.201
≤0.5 D (95% CI) 80.6% (75.1, 86.2) 82.0% (78.5, 85.5) 0.671 ≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	Barrett Univ. 2			
≤1.0 D (95% CI) 97.5% (95.2, 99.7) 98.3% (97.0, 99.5) 0.505 Holladay 2 ≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤0.25 D (95% CI)	51.0% (44.0, 58.0)	51.5% (47.0, 56.1)	0.904
Holladay 2 ≤0.25 D (95% CI) ≤0.5 D (95% CI) ≤0.5 D (95% CI) ≤1.0 D (95% CI) ≤0.5 D (95% CI) 20.5 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 80.64 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤0.5 D (95% CI)	80.6% (75.1, 86.2)	82.0% (78.5, 85.5)	0.671
≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤1.0 D (95% CI)	97.5% (95.2, 99.7)	98.3% (97.0, 99.5)	0.505
≤0.25 D (95% CI) 50.5% (43.5, 57.5) 49.8% (45.2, 54.4) 0.864 ≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	Holladay 2			
≤0.5 D (95% CI) 80.1% (74.5, 85.7) 82.5% (79.0, 86.0) 0.476 ≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	· '	50.5% (43.5, 57.5)	49.8% (45.2, 54.4)	0.864
≤1.0 D (95% CI) 96.9% (94.5, 99.4) 98.7% (97.6, 99.7) 0.128 Olsen ≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	, ,	, , ,	, ,	0.476
≤0.25 D (95% CI) 49.0% (42.0, 56.0) 49.6% (45.0, 54.2) 0.892 ≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	≤I.0 D (95% CI)	96.9% (94.5, 99.4)	98.7% (97.6, 99.7)	0.128
≤0.5 D (95% CI) 79.6% (74.0 85.2) 81.8% (78.3, 85.3) 0.509	Olsen			
	≤0.25 D (95% CI)	49.0% (42.0, 56.0)	49.6% (45.0, 54.2)	0.892
≤1.0 D (95% CI) 98.0% (96.0, 99.9) 98.7% (97.6, 99.7) 0.490	≤0.5 D (95% CI)	79.6% (74.0 85.2)	81.8% (78.3, 85.3)	0.509
	≤1.0 D (95% CI)	98.0% (96.0, 99.9)	98.7% (97.6, 99.7)	0.490

Note: *p value relates to difference in proportions between groups. **Abbreviations:** Cl, confidence interval; D, dioptres.

formulas^{1–3} to predict refractive accuracy. To the best of our knowledge, the only study using a later generation formula, was an intraindividual RCT of 110 paired eyes by Dzhaber³⁵ which used the Holladay 2 formula and did not demonstrate any difference. With this formula they reported similar values to other studies with 81/84% (p=0.17) of cases within 0.5D of the anticipated outcome. We hypothesized that when these modern formulas are used, there may be a refractive benefit for FLACS not evident with third generation formulas.

Ours is the first study that compared refractive prediction outcomes of FLACS and CCS using IOL constant optimization and included only one eye per patient as per the published recommendation.⁸ The recommendation to perform IOL constant optimization allows a more reliable comparison between formulas, with any difference in absolute error likely to reflect a true difference in formula accuracy. However, despite optimizing IOL constants in our study, the refractive accuracy was very similar to large prospective FEMCAT⁴ and FACT⁵ trials which did not perform optimization. Results of our study reconfirms that although the capsulotomy performed by FLACS may appear much more central and circular as compared to CCS, it does not translate in to better ELP and achieving more accurate refractive outcomes.

FLACS cases have also been demonstrated to show less capsular bag²⁶ and capsulotomy shrinkage²¹ at 1-3 months. It is also possible that these longer-term shrinkage forces are distributed relatively less symmetrically to the more irregular, less centered CCS capsulotomy and therefore more likely to induce long term IOL tilt, decentration and refractive change. This may be beneficial in the longer term for patients with multifocal and extended depth of focus lenses where lens tilt and decentration would degrade the visual outcome. A study using these lenses with longer term follow up would help address this question. A recent meta-analysis and commentary^{36,37} reported a clinically but not statistically significant lower rate of posterior capsule rupture with LACS, which would also benefit refractive outcome since IOL position is less predictable in these cases.

Overall, our study did not find any refractive advantage for FLACS over CCS when using modern IOL formulas and optimized IOL constants during a short-term follow-up. This confirms that a refractive advantage should not be used in guiding a patient's decision to proceed with either technique.

A disadvantage of our study is the potential for bias associated with patient self-selection for the either procedure. FLACS incurs an increased patient out of pocket expense in Australia of \$AUD850 (equivalent to \$US550 or 500euros).

The strengths of this study include that the surgeries were performed by a single surgeon, consistent staff performed the follow up assessments and modern biometry (IOLMaster model 700) was used. In addition, few patients were lost to follow up, the series was relatively large, and a systematic approach taken to case exclusion.

Connell et al Dovepress

Conclusion

Our study found no difference in refractive outcome prediction accuracy between the CCS and FLACS techniques using modern IOL formulas and optimized constants.

Acknowledgments

Sophie Rogers provided statistical support.

Disclosure

Jack X. Kane is the owner of the Kane formula. The authors report no other conflicts of interest in this work.

References

- Melles RB, Holladay JT, Chang WJ. Accuracy of intraocular lens calculation formulas. *Ophthalmology*. 2018;125:169–178. doi:10.1016/j.ophtha.2017.08.027
- Melles RB, Kane JX, Olsen T, Chang WJ. Update on intraocular lens calculation formulas. *Ophthalmology*. 2019;126:1334–1335. doi:10.1016/j.ophtha.2019.04.011
- Darcy K, Gunn D, Tavassoli S, Sparrow J, Kane JX. Assessment of the accuracy of new and updated intraocular lens power calculation formulas in 10 930 eyes from the UK National Health Service. J Cataract Refract Surg. 2020;46:2–7. doi:10.1016/j.jcrs.2019.08.014
- Schweitzer C, Brezin A, Cochener B, et al. Femtosecond laser-assisted versus phacoemulsification cataract surgery (FEMCAT): a multicentre participant-masked randomised superiority and cost-effectiveness trial. *Lancet*. 2020;395:212–224. doi:10.1016/ S0140-6736(19)32481-X
- Day AC, Burr JM, Bennett K, et al. Femtosecond laser-assisted cataract surgery versus phacoemulsification cataract surgery (FACT): a randomized noninferiority trial. *Ophthalmology*. 2020;127:1012–1019. doi:10.1016/j.ophtha.2020.02.028
- 6. Berk TA, Schlenker MB, Campos-Moller X, Pereira AM, Ahmed IIK. Visual and refractive outcomes in manual versus femto-second laser-assisted cataract surgery: a single-center retrospective cohort analysis of 1838 eyes. *Ophthalmology*. 2018;125:1172–1180. doi:10.1016/j.ophtha.2018.01.028
- Chee SP, Yang Y, Ti SE. Clinical outcomes in the first two years of femtosecond laser-assisted cataract surgery. Am J Ophthalmol. 2015;159:714–719. doi:10.1016/j.ajo.2015.01.016
- Hoffer KJ, Aramberri J, Haigis W, et al. Protocols for studies of intraocular lens formula accuracy. Am J Ophthalmol. 2015;160:403– 405 e1. doi:10.1016/j.ajo.2015.05.029
- Nagy ZZ, Kranitz K, Takacs AI, Mihaltz K, Kovacs I, Knorz MC. Comparison of intraocular lens decentration parameters after femtosecond and manual capsulotomies. *J Refract Surg.* 2011;27:564–569. doi:10.3928/1081597X-20110607-01
- Kranitz K, Mihaltz K, Sandor GL, Takacs A, Knorz MC, Nagy ZZ. Intraocular lens tilt and decentration measured by Scheimpflug camera following manual or femtosecond laser-created continuous circular capsulotomy. *J Refract Surg.* 2012;28:259–263. doi:10.3928/1081597X-20120309-01
- Haigis W, Lege B, Miller N, Schneider B. Comparison of immersion ultrasound biometry and partial coherence interferometry for intraocular lens calculation according to Haigis. *Graefes Arch Clin Exp* Ophthalmol. 2000;238:765–773. doi:10.1007/s004170000188
- Hoffer KJ. The Hoffer Q formula: a comparison of theoretic and regression formulas. J Cataract Refract Surg. 1993;19:700–712. doi:10.1016/S0886-3350(13)80338-0

 Zuberbuhler B, Morrell AJ. Errata in printed Hoffer Q formula. J Cataract Refract Surg. 2007;33:2;author reply 2–3. doi:10.1016/j. jcrs.2006.08.054

- Holladay JT, Prager TC, Chandler TY, Musgrove KH, Lewis JW, Ruiz RS. A three-part system for refining intraocular lens power calculations. *J Cataract Refract Surg.* 1988;14:17–24. doi:10.1016/ S0886-3350(88)80059-2
- Retzlaff JA, Sanders DR, Kraff MC. Development of the SRK/T intraocular lens implant power calculation formula. *J Cataract Refract Surg.* 1990;16:333–340. doi:10.1016/S0886-3350(13)80705-5
- Kane JX, Van Heerden A, Atik A, Petsoglou C. Intraocular lens power formula accuracy: comparison of 7 formulas. *J Cataract Refract Surg.* 2016;42:1490–1500. doi:10.1016/j.jcrs.2016.07.021
- Olsen T. PhacoOptics. Available from: https://www.phacooptics.net/. Accesed October 1, 2019.
- 18. Holladay JT. Holladay IOL Consultant Software & Surgical Outcomes Assessment. Bellaire, TX: Holladay Consulting; 2015.
- Barrett GD. Barrett Universal II Formula. Singapore: Asia-Pacific Association of Cataract and Refractive Surgeons; 2018.
- Wang L, Koch DD, Hill W, Abulafia A. Pursuing perfection in intraocular lens calculations: III. Criteria for analyzing outcomes. *J Cataract Refract Surg.* 2017;43:999–1002. doi:10.1016/j. jcrs.2017.08.003
- Panthier C, Costantini F, Rigal-Sastourne JC, et al. Change of capsulotomy over 1 year in femtosecond laser-assisted cataract surgery and its impact on visual quality. *J Refract Surg.* 2017;33:44–49. doi:10.3928/1081597X-20161028-01
- Friedman NJ, Palanker DV, Schuele G, et al. Femtosecond laser capsulotomy. J Cataract Refract Surg. 2011;37:1189–1198. doi:10.1016/j.jcrs.2011.04.022
- Mastropasqua L, Toto L, Mattei PA, et al. Optical coherence tomography and 3-dimensional confocal structured imaging system-guided femtosecond laser capsulotomy versus manual continuous curvilinear capsulorhexis. *J Cataract Refract Surg.* 2014;40:2035–2043. doi:10.1016/j.jcrs.2014.05.032
- 24. Kranitz K, Takacs A, Mihaltz K, Kovacs I, Knorz MC, Nagy ZZ. Femtosecond laser capsulotomy and manual continuous curvilinear capsulorrhexis parameters and their effects on intraocular lens centration. *J Refract Surg.* 2011;27:558–563. doi:10.3928/1081597X-20110623-03
- Ostovic M, Klaproth OK, Hengerer FH, Mayer WJ, Kohnen T. Light microscopy and scanning electron microscopy analysis of rigid curved interface femtosecond laser-assisted and manual anterior capsulotomy. *J Cataract Refract Surg.* 2013;39:1587–1592. doi:10.1016/j.jcrs.2013.07.024
- Dick HB, Conrad-Hengerer I, Schultz T. Intraindividual capsular bag shrinkage comparing standard and laser-assisted cataract surgery. J Refract Surg. 2014;30:228–233. doi:10.3928/1081597X-201403 20-01
- Norrby S. Sources of error in intraocular lens power calculation.
 J Cataract Refract Surg. 2008;34:368–376. doi:10.1016/j.jcrs.20
 07.10.031
- Roberts HW, Wagh VK, Sullivan DL, et al. A randomized controlled trial comparing femtosecond laser-assisted cataract surgery versus conventional phacoemulsification surgery. *J Cataract Refract Surg*. 2019;45:11–20. doi:10.1016/j.jcrs.2018.08.033
- Krarup T, Ejstrup R, Mortensen A, la Cour M, Holm LM. Comparison
 of refractive predictability and endothelial cell loss in femtosecond
 laser-assisted cataract surgery and conventional phaco surgery: prospective randomised trial with 6 months of follow-up. *BMJ Open Ophthalmol.* 2019;4:e000233. doi:10.1136/bmjophth-2018-000233
- 30. Manning S, Barry P, Henry Y, et al. Femtosecond laser-assisted cataract surgery versus standard phacoemulsification cataract surgery: study from the European Registry of Quality Outcomes for Cataract and Refractive Surgery. *J Cataract Refract Surg.* 2016;42:1779–1790. doi:10.1016/j.jcrs.2016.10.013

Dovepress Connell et al

- 31. Ewe SY, Abell RG, Oakley CL, et al. A comparative cohort study of visual outcomes in femtosecond laser-assisted versus phacoemulsification cataract surgery. Ophthalmology. 2016;123:178-182. doi:10.1016/j.ophtha.2015.09.026
- 32. Filkorn T, Kovacs I, Takacs A, Horvath E, Knorz MC, Nagy ZZ. Comparison of IOL power calculation and refractive outcome after laser refractive cataract surgery with a femtosecond laser versus conventional phacoemulsification. J Refract Surg. 2012;28:540-544. doi:10.3928/1081597X-20120703-04
- 33. Conrad-Hengerer I, Al Sheikh M, Hengerer FH, Schultz T, Dick HB. Comparison of visual recovery and refractive stability between femtosecond laser-assisted cataract surgery and standard phacoemulsification: six-month follow-up. J Cataract Refract Surg. 2015;41:1356-1364. doi:10.1016/j.jcrs.2014.10.044
- 34. Nithianandan H, Jegatheeswaran V, Dalal V, et al. Refractive laser-assisted cataract surgery vs. conventional manual surgery: comparing efficacy and safety in 3144 eyes. Am J Ophthalmol. 2019.

- 35. Dzhaber D, Mustafa OM, Alsaleh F, Daoud YJ, Daoud YJ. Visual and refractive outcomes and complications in femtosecond laser-assisted versus conventional phacoemulsification cataract surgery: findings from a randomised, controlled clinical trial. Br J Ophthalmol. 2020;104:225-229. doi:10.1136/bjophthalmol-2018-313723
- 36. Kolb CM, Shajari M, Mathys L, et al. Comparison of femtosecond laser-assisted cataract surgery and conventional cataract surgery: a meta-analysis and systematic review. J Cataract Refract Surg. 2020;46:1075-1085. doi:10.1097/j.jcrs.0000000000000228
- 37. Levitz LM, Wendell JS, Lawless M, Dick HB, Nagy Z. Comment on: comparison of femtosecond laser-assisted cataract surgery and conventional cataract surgery and conventional cataract surgery: a meta-analysis and systematic review. J Cataract Refract Surg. 2021;47:278. doi:10.1097/j.jcrs.0000000000000534

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry, Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed

Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/clinical-ophthalmology-journal

Dovepress